Company-wide revenue
Reported revenue in 2021 ¥2.59T Reported revenue in 2025 ¥3.1T
- growth amount
- +¥518.42B
- growth annualized
- +4.7%
- growth total
- +20.0%
Japanese company profile · 2784
Alfresa Holdings Corporation
In its FY2025 public filing, Alfresa Holdings Corporation reports Wholesale of Prescription Medicines and Related Products, Self-medication wholesale, Manufacturing of pharmaceuticals and related products, Pharmacy and related activities. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: アルフレッサホールディングス株式会社
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
Alfresa Holdings Corporation's largest reported business by revenue in FY2025 was Wholesale of Prescription Medicines and Related Products.
The business with the highest reported segment profit in FY2025 was Wholesale of Prescription Medicines and Related Products.
FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Sales | Revenue share | Operating profit |
|---|---|---|---|
| Wholesale of Prescription Medicines and Related Products | ¥2.78T ↗ | 89.6% | ¥33.3B ↗ |
| Self-medication wholesale | ¥267.07B ↗ | 8.6% | ¥3.01B ↗ |
| Manufacturing of pharmaceuticals and related products | ¥52.18B ↗ | 1.7% | ¥1.2B ↗ |
| Pharmacy and related activities | ¥37.17B ↗ | 1.2% | ¥499M ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Wholesale of Prescription Medicines and Related Products
- 医療用医薬品等卸売事業
- Self-medication wholesale
- セルフメディケーション卸売事業
- Manufacturing of pharmaceuticals and related products
- 医薬品等製造事業
- Pharmacy and related activities
- 調剤薬局等事業
- Healthcare-related Business
- 医療関連事業
- Sales
- 売上高
- Operating profit
- 営業利益
Original Japanese label
- Wholesale of Prescription Medicines and Related Products
- 医療用医薬品等卸売事業
- Self-medication wholesale
- セルフメディケーション卸売事業
- Manufacturing of pharmaceuticals and related products
- 医薬品等製造事業
- Pharmacy and related activities
- 調剤薬局等事業
- Healthcare-related Business
- 医療関連事業
- Sales
- 売上高
- Operating profit
- 営業利益
Reported Sales by business over time
Reported Sales by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Wholesale of Prescription Medicines and Related Products | ¥2.29T | ¥2.4T | ¥2.54T | ¥2.64T | ¥2.78T |
| Self-medication wholesale | ¥244.82B | ¥246.68B | ¥262.84B | ¥265.75B | ¥267.07B |
| Manufacturing of pharmaceuticals and related products | ¥47.36B | ¥49.04B | ¥52.74B | ¥54.06B | ¥52.18B |
| Pharmacy and related activities | ¥34.47B | ¥36.2B | ¥36.65B | ¥37.02B | ¥37.17B |
| Healthcare-related Business | ¥34.47B | ¥36.2B | ¥36.65B | ¥37.02B | ¥37.17B |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
Business revenue growth
Wholesale of Prescription Medicines and Related Products
Reported revenue in 2021 ¥2.29T Reported revenue in 2025 ¥2.78T
- growth amount
- +¥494.48B
- growth annualized
- +5.0%
- growth total
- +21.6%
View original filing
Self-medication wholesale
Reported revenue in 2021 ¥244.82B Reported revenue in 2025 ¥267.07B
- growth amount
- +¥22.25B
- growth annualized
- +2.2%
- growth total
- +9.1%
View original filing
Manufacturing of pharmaceuticals and related products
Reported revenue in 2021 ¥47.36B Reported revenue in 2024 ¥54.06B
- growth amount
- +¥6.71B
- growth annualized
- +4.5%
- growth total
- +14.2%
View original filing
Manufacturing of pharmaceuticals and related products
Reported profit margin in 2022 +0.9%
Reported profit margin in 2025 +2.3%
- growth margin points
- +1.4
View original filing
Healthcare-related Business
Reported profit margin in 2021 +0.5%
Reported profit margin in 2024 +1.6%
- growth margin points
- +1.1
View original filing
Self-medication wholesale
Reported profit margin in 2022 +0.9%
Reported profit margin in 2025 +1.1%
- growth margin points
- +0.3
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YH29
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.